Estrogen Receptor-{alpha} Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer.
(2009) In Journal of the National Cancer Institute 101(24). p.1725-1729- Abstract
- Although estrogen receptor-alpha (ERalpha) is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ERalpha-positive breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ERalpha at serine-118 (ERalphaS118-P) is required for tamoxifen-mediated inhibition of ERalpha-induced gene expression. We evaluated the association between recurrence-free survival after tamoxifen treatment and ERalphaS118-P expression by use of Cox proportional hazards regression. Data were from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs no systemic treatment. ERalphaS118-P... (More)
- Although estrogen receptor-alpha (ERalpha) is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ERalpha-positive breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ERalpha at serine-118 (ERalphaS118-P) is required for tamoxifen-mediated inhibition of ERalpha-induced gene expression. We evaluated the association between recurrence-free survival after tamoxifen treatment and ERalphaS118-P expression by use of Cox proportional hazards regression. Data were from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs no systemic treatment. ERalphaS118-P expression was assessed by immunohistochemistry and categorized by use of the Allred score (low expression = score of 0-6; high expression = score of 7-8). All statistical tests were two-sided. Compared with systemically untreated patients, we found evidence of a benefit from adjuvant tamoxifen among patients whose tumors had high ERalphaS118-P expression (23.7 recurrences per 1000 person-years versus 72.2 recurrences per 1000 person-years, hazard ratio [HR] of recurrence = 0.36, 95% confidence interval [CI] = 0.20 to 0.65) but not among patients whose tumors had low expression (51.0 recurrences per 1000 person-years versus 57.0 recurrences per 1000 person-years, HR of recurrence = 0.87, 95% CI = 0.51 to 1.48. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1511542
- author
- Kok, Marleen ; Wigerup, Caroline LU ; Hauptmann, Michael ; Michalides, Rob ; Stål, Olle ; Linn, Sabine and Landberg, Göran LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of the National Cancer Institute
- volume
- 101
- issue
- 24
- pages
- 1725 - 1729
- publisher
- Oxford University Press
- external identifiers
-
- wos:000272933400011
- pmid:19940281
- scopus:72649090647
- pmid:19940281
- ISSN
- 1460-2105
- DOI
- 10.1093/jnci/djp412
- language
- English
- LU publication?
- yes
- id
- c6f5f619-b816-4ad2-8211-737973c5d84b (old id 1511542)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19940281?dopt=Abstract
- date added to LUP
- 2016-04-01 14:32:07
- date last changed
- 2022-01-28 01:08:25
@article{c6f5f619-b816-4ad2-8211-737973c5d84b,
abstract = {{Although estrogen receptor-alpha (ERalpha) is a marker used to identify breast cancer patients most likely to benefit from endocrine therapy, approximately 50% of ERalpha-positive breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that phosphorylation of ERalpha at serine-118 (ERalphaS118-P) is required for tamoxifen-mediated inhibition of ERalpha-induced gene expression. We evaluated the association between recurrence-free survival after tamoxifen treatment and ERalphaS118-P expression by use of Cox proportional hazards regression. Data were from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs no systemic treatment. ERalphaS118-P expression was assessed by immunohistochemistry and categorized by use of the Allred score (low expression = score of 0-6; high expression = score of 7-8). All statistical tests were two-sided. Compared with systemically untreated patients, we found evidence of a benefit from adjuvant tamoxifen among patients whose tumors had high ERalphaS118-P expression (23.7 recurrences per 1000 person-years versus 72.2 recurrences per 1000 person-years, hazard ratio [HR] of recurrence = 0.36, 95% confidence interval [CI] = 0.20 to 0.65) but not among patients whose tumors had low expression (51.0 recurrences per 1000 person-years versus 57.0 recurrences per 1000 person-years, HR of recurrence = 0.87, 95% CI = 0.51 to 1.48.}},
author = {{Kok, Marleen and Wigerup, Caroline and Hauptmann, Michael and Michalides, Rob and Stål, Olle and Linn, Sabine and Landberg, Göran}},
issn = {{1460-2105}},
language = {{eng}},
number = {{24}},
pages = {{1725--1729}},
publisher = {{Oxford University Press}},
series = {{Journal of the National Cancer Institute}},
title = {{Estrogen Receptor-{alpha} Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer.}},
url = {{http://dx.doi.org/10.1093/jnci/djp412}},
doi = {{10.1093/jnci/djp412}},
volume = {{101}},
year = {{2009}},
}